News for BeiGene Ltd (spons. ADRs)

TipRanks 136d

BeiGene’s Strategic Growth and Global Expansion Underpin Buy Rating

Seeking Alpha 146d

Catalyst Watch: Netflix earnings, Monster Beverage event, drug data, and quantum volatility

TipRanks 146d

Hold Rating on BeiGene: Balancing Pipeline Progress with Market Challenges

TipRanks 148d

BeiGene’s Path to Financial Stability and Growth: A Buy Recommendation by Jill Wu

TipRanks 161d

Ten new option listings and five option delistings on January 2nd

TipRanks 167d

Netflix draws big viewership for NFL Christmas games: Morning Buzz

TipRanks 167d

Morning Movers: Arena climbs after NYSE acceptance of plan to regain compliance

Seeking Alpha 167d

BeiGene wins FDA nod for Tevimbra in gastric cancer

TipRanks 167d

BeiGene announces FDA approval of Tevimbra

TipRanks 171d

BeiGene to change ticker symbol to ‘ONC’ on January 2, 2025

TipRanks 176d

BeiGene gets FDA orphan designation in Waldenstrom macroglobulinemia treatment

TipRanks 176d

BeiGene’s Strategic Advancements and Promising Clinical Developments Justify Buy Rating

TipRanks 177d

BeiGene’s Strategic Advancements and Promising Pipeline Drive Buy Rating

TipRanks 177d

BeiGene (BGNE) Gets a Buy from TD Cowen

TipRanks 177d

BeiGene: Promising Growth Trajectory and Investment Opportunity Backed by Strong Product Pipeline and Robust Financials

TipRanks 181d

Biotech Alert: Searches spiking for these stocks today

TipRanks 182d

BeiGene announces global licensing agreement for MAT2A inhibitor

TipRanks 183d

BeiGene’s Strong Pipeline and Financial Position Make It a Compelling Buy Opportunity

TipRanks 184d

BeiGene’s Promising CLL Market Potential: Buy Rating Driven by Strong BTK Degrader Data and Competitive Edge

TipRanks 185d

BeiGene discloses new data in BRUKINSA, promising advancements pipeline at ASH

TipRanks 189d

Morgan Stanley Reaffirms Their Buy Rating on BeiGene (BGNE)

Seeking Alpha 191d

BeiGene started at overweight at Morgan Stanley on Brukinsa market share growth

TipRanks 191d

BeiGene assumed with an Overweight at Morgan Stanley

TipRanks 196d

Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE) and Teladoc (TDOC)

Seeking Alpha 197d

European Commission approves products by BeiGene, GSK and Novartis

TipRanks 197d

BeiGene announces EC approval of Tevimbra

TipRanks 205d

Labcorp CFO Glenn Eisenberg to retire, Julia Wang to succeed

TipRanks 205d

BeiGene settles litigation against generic filer of Brukinsa

TipRanks 210d

BeiGene announces proposed name change to ‘BeOne Medicines’

TipRanks 210d

BeiGene: Balancing Promising Sales Growth with Operational Challenges – Hold Rating Recommended

TipRanks 210d

BeiGene: Strong Buy Recommendation Driven by Impressive Sales Growth and Promising Pipeline

TipRanks 210d

BeiGene’s Strong Financial Performance and Growth Potential Justifies Buy Rating

TipRanks 210d

BeiGene Reports Strong Revenue Growth in Q3 2024

TipRanks 211d

BeiGene price target raised to $260 from $254 at TD Cowen

TipRanks 211d

BeiGene’s Financial and Market Challenges: Navigating Risks in Drug Acceptance, Competition, and Geopolitical Tensions

TipRanks 212d

BeiGene’s Strong Performance and Promising Pipeline Drive Buy Rating

Seeking Alpha 212d

BeiGene GAAP EPADS of -$1.15 misses by $0.16, revenue of $1B beats by $15.76M

TipRanks 212d

BeiGene reports Q3 EPS ($1.15), consensus ($1.20)

TipRanks 213d

BeiGene: Strong Revenue Outlook and Innovative Cancer Treatments Drive Buy Recommendation

TipRanks 219d

BeiGene to share new Brukinsa data at ASH Annual Meeting

Seeking Alpha 223d

Zymeworks drops as Wells Fargo cuts on valuation

Seeking Alpha 233d

Indaptus Therapeutics signs clinical supply agreement with Beigene

TipRanks 233d

Indaptus Therapeutics announces clinical supply agreement with BeiGene

TipRanks 233d

BeiGene price target raised to $235 from $200 at JPMorgan

TipRanks 234d

TD Cowen Keeps Their Buy Rating on BeiGene (BGNE)

TipRanks 234d

BeiGene receives positive CHMP opinions for tevimbra in gastric cancers

Seeking Alpha 251d

Chinese biotechs gain as drugmakers targeted in new security bill said to mull divestments

TipRanks 255d

BeiGene: A Strong Buy on Robust R&D, Global Expansion, and Market Outperformance

Seeking Alpha 259d

Merck, Bristol-Myers fail to convince FDA AdCom on wider Opdivo, Keytruda use

Seeking Alpha 261d

Bristol, Merck checkpoint inhibitors focus of FDA advisory committee meeting

	
		OSZAR »